Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alligator Bioscience AB ( (SE:ATORX) ) has provided an announcement.
Alligator Bioscience announced that new data from an investigator-initiated Phase 1 trial of intratumoral mitazalimab in combination with irreversible electroporation in locally advanced pancreatic ductal adenocarcinoma will be presented at the AACR Annual Meeting 2026 in San Diego. The study, led by UC San Diego’s Dr. Rebekah R. White, will detail how a CD40 antibody-based approach may boost T cell reactivity to personalized neoantigens, underscoring mitazalimab’s potential to enhance immunotherapy outcomes in a hard-to-treat cancer and reinforcing Alligator’s profile in cutting-edge pancreatic cancer research.
The presentation focuses on combining mitazalimab with irreversible electroporation to improve immune response in locally advanced pancreatic cancer, highlighting a novel strategy in tumor-directed immunotherapy. By securing a scientific platform at AACR 2026 for its CD40-focused program, Alligator strengthens its visibility in the oncology community and supports the clinical rationale for advancing mitazalimab in multiple cancer indications.
The most recent analyst rating on (SE:ATORX) stock is a Sell with a SEK0.16 price target. To see the full list of analyst forecasts on Alligator Bioscience AB stock, see the SE:ATORX Stock Forecast page.
More about Alligator Bioscience AB
Alligator Bioscience AB is a Swedish biotechnology company developing clinical-stage, tumor-directed antibody drugs focused on the CD40 receptor in immuno-oncology. Its lead candidate, mitazalimab, is ready for Phase 3 development and has shown strong survival data in metastatic pancreatic cancer, positioning the company as a niche player in advanced cancer therapeutics.
YTD Price Performance: -43.75%
Average Trading Volume: 5,326,688
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK101M
Find detailed analytics on ATORX stock on TipRanks’ Stock Analysis page.